Cylene Pharmaceuticals Raises $26.3 Million in Series B Financing

Cylene Pharmaceuticals, an oncology drug discovery and development company, announced the completion of a $26.3 million Series B financing, led by Coastview Capital. The funding will allow Cylene to advance CX-3543, its lead product for the treatment of multiple cancers, into clinical development. William Rice, Ph.D., President and CEO of Cylene announced the financing at the 7th Annual C21 BioVentures Conference in Monterey, California.

()a href="http://www.biospace.com/news_story.cfm?StoryID=20180520&full=1" target="_blank">BioSpace